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AIMS 
 
 
 
 
1. To compare laparoscopic & open surgery for rectal cancer after 
neoadjuvant chemoradiation in terms of acute morbidity. 
 
2. To assess oncological efficacy in terms of nodal yield and 
circumferential resection margin. 
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BACKGROUND 
 
 
 
 
 Preoperative chemoradiotherapy, as compared with postoperative 
chemoradiotherapy, improved local control & was associated with 
reduced toxicity although it didn’t improve survival1. Thus preoperative 
chemoradiotherapy can be considered standard of care for locally 
advanced rectal cancer. Laparoscopic assisted surgery for colon cancer is 
as effective as open surgery in the short term & is likely to produce 
similar long-term outcomes2. However, impaired short-terms outcomes 
after laparoscopic assisted anterior resection for cancer of rectum do not 
yet justify its routine use. Furthermore, there is very limited data 
available on role of laparoscopy surgery for rectal cancer following 
neoadjuvant chemoradiation.  
  3
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 Globally, nearly 800,000 new colorectal cancer cases are believed 
to occur, which accounted for approximately 10% of all incident cancers, 
and mortality from colorectal cancer was estimated at nearly 450,000 3. 
In India, most of the patients presents with locally advanced rectal 
cancer (T3/T4, N+, As per UICC staging manual) & treatment involves 
multimodality treatment.  
 
 The last two decades have seen major advances in the 
understanding of the natural history of rectal cancer and its patterns of 
recurrence. This progress has led to significant improvements in 
treatment, especially for patients with clinically resectable rectal cancers, 
where surgery remains the cornerstone of treatment, and has driven 
technical advances in surgical technique with the increasing use of 
meticulous sharp dissection and total mesorectal excision (TME). Few 
recent surgical series suggest that TME is associated with much lower 
rates of local recurrence, even when employed in stage III patients46. 
  4
Consequently the role of adjuvant treatment with radiotherapy or 
chemoradiotherapy has also evolved with changing surgical practice and 
outcomes.  
 
 Since it was first reported 20 years ago, laparoscopic rectal 
resection has been performed increasingly for benign and malignant 
rectal diseases 7. Minimally invasive , laparoscopically assisted surgery 
was first considered in 1990 for patients undergoing colectomy for 
cancer8.Concern that this approach would compromise survival by 
failing to achieve a proper oncologic resection or adequate staging or by 
altering patterns of recurrence (based on frequent reports of tumor 
recurrences within surgical wounds) promped a controlled trial 
evaluation. Current practice of laparoscopic surgery for rectal cancer 
depends on extrapolation of data from colon cancer trials. So far, five 
randomized trials reported survival data, all supporting non-inferiority of 
laparoscopy.2,9,10,11,12 
 
 COST (Clinical outcomes of surgical therapy) study group 9 
conducted a noninferiority trial at 48 institutions and randomly assigned 
872 patients with adenocarcinoma of the colon to undergo open or 
laparoscopically assessed colectomy performed by credentialed surgeons 
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. The median follow-up was 4.4 years. The primary end point was the 
time to tumor recurrence.  
 
 At three years , the rates of recurrence were similar in the two 
groups- 16 percent among patients in the group that underwent 
laparoscopically assisted surgery and 18 percent among patients in the 
open-colectomy group ( two-sided p=0.32; hazard ratio for 
recurrence,0.86; 95 percent confidence interval,0.63 to 1.17). Recurrence 
rates in surgical wounds were less than 1 percent in both groups               
( p=0.50). The overall survival rate at three years was also very similar 
in the two groups ( 86 percent in the laparoscopic surgery group and 85 
percent in the open-colectomy group; p=0.51; hazard ratio for death in 
the laparoscopic –surgery group, 0.91; 95 percent confidence interval , 
0.68 to 1.21), with no significant difference between groups in the time 
to recurrence or overall survival for patients with any stage of cancer 
.Perioperative recovery was faster in the laparoscopic – surgery group 
than in the open- colectomy group, as reflected by a shorter median 
hospital stay (five days Vs six days , p<0.001) and briefer use of 
parenteral narcotics (three days Vs four days , p<0.001) and oral 
analgesics (one day Vs two days, p= 0.02). The rate of intraoperative 
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complications, 30-day postoperative mortality complications at discharge 
and 60 days, hospital readmission, and reoperation were very similar 
between groups.  
 
 In this multi-institutional study, the rates of recurrent cancer were 
similar after laparoscopically assisted colectomy and open colectomy, 
suggesting that the laparoscopic approach is an acceptable alternative to 
open surgery for colon cancer.  
 
 Although early reports on laparoscopic assisted colectomy (LAC) 
in patients with colon cancer suggested that it reduces perioperative 
morbidity, its influence on long-term results is unknown. Spanish single 
centre trial 10 done at IDIBAPS, University of Barcelona recruited 
patients with adenocarcinoma of colon from Nov 1993 to July, 1998. 219 
patients took part in study ( 111 LAC group, 108 Open Colectomy 
group). Patients in LAC group recovered faster than those in the OC 
group, with shorter peristalsis-detection (p=0.001) and oral intake time 
(p=0.001), and shorter hospital stays (p=0.005). Morbidity was lower in 
the LAC group (p=0.001), although LAC did not influence perioperative 
mortality. Probability of cancer –related survival was higher in the LAC 
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group (p=0.02). The Cox model showed that LAC was independently 
associated with reduced risk of tumour relapse (hazard ratio 0.39, 95 
percent confidence interval 0.19-0.82), death from any cause (0.48, 0.23-
1.01) and death from a cancer related cause compared with open 
colectomy. This superiority of LAC was due to differences in patients 
with stage III tumors (freedom from recurrence, p=0.04, overall survival, 
p=0.02, and cancer-related survival, p=0.006 ). By contrast, in patients 
with stage I and II tumors, these variables were almost identical in both 
therapeutic groups. The improvement in tumor recurrence and survival 
in patients with stage III tumors operated on be LAC was of such 
magnitude that they were similar to those observed in patients with stage 
II tumors. Probable reason for this difference in survival might be due to 
evidence that surgical stress impairs immunity and that this feature is 
more intense in open surgery than in laparoscopic surgery. Immunity has 
a critical role in tumor progression and metastatic spread. This 
association could explain above findings from Spanish trial that LAC is 
associated with better outcomes only in stage III tumors. In stage I and II 
tumors, the probability of dissemination is very low and probably not 
affected by changes in immunological status. However, this situation 
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could not be the case in patients with stage III tumors, in whom a normal 
immunity may be essential to prevent tumor dissemination.  
 
 Of the few multicenter randomized, controlled trials initiated in 
the 1990s, the United Kingdom Medical Research Council trial of 
conventional Vs laparoscopic-assisted surgery in colorectal cancer (UK 
MRC CLASICC) 2 was the only one that did not exclude rectal cancer. 
Primary short-term endpoints were the rate of positive circumferential 
margins (CRMs) and longitudinal resection margins, proportion of 
Dukes' C2 tumors (ie, T3 and apical node metastasis), and in-hospital 
mortality. Patients were randomized to the laparoscopic arm in a 2:1 
ratio. Of the 794 patients recruited to the trial, 381 had rectal cancer. Of 
these, 132 (48%) underwent open resection and 160 (46%) received 
laparoscopic-assisted resection. The overall conversion rate from 
laparoscopic to open surgery within the rectal cohort was 34% (82 of 
242 patients). Within the actual treatment group, 87 patients (51 anterior 
resections and 36 APRs) underwent open TME; 189 patients (129 
anterior resections and 60 APRs) underwent laparoscopic TME. The 
greater proportion of patients undergoing TME in the laparoscopic 
anterior resection group, despite the fact that the median distance of 
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rectal tumors from the anal verge was similar in both study groups, may 
be related to the inability of the surgeon to palpate the tumor during 
laparoscopic surgery. It has been hypothesized that TME was more 
commonly performed to ensure adequacy of the distal resection margin.  
 
 Positive CRMs were identified in 14% of patients who underwent 
open resection and 16% of those who had laparoscopic resection 
(P=.80). Among patients undergoing anterior resection, CRM positivity 
was 12% in the laparoscopic group Vs 6% in the open group (P=.19). 
Among patients undergoing APR, no difference in CRM positivity was 
noted between the laparoscopic and open groups (20% Vs 26%, 
respectively). Longitudinal resection margins were not significantly 
different between the two treatment arms. Although the proportion of 
Dukes C2 tumors was similar in both groups, a higher proportion was 
seen in patients whose procedures were converted from laparoscopic to 
open compared with those who were initially randomized to the open 
arm. However, after adjustment for stratification factors, this difference 
was not statistically significant (P=.12). In-hospital mortality rates were 
5% after open surgery Vs 4% after laparoscopic surgery (P=.57). 
Patients whose procedures were converted from laparoscopic to open 
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had a higher mortality rate compared with patients in the open and 
laparoscopic arms, but this difference was not significant (P=.34). The 
main cause of death was cardiorespiratory failure. In view of the 
nonsignificant but concerning higher CRM positivity rate found in 
patients who underwent laparoscopic anterior resection, the authors 
concluded that routine use of laparoscopic resection for rectal cancer was 
not yet justified. 
 
 In 2007, the UK MRC CLASICC trial19 reported its long-term 
outcomes based primarily on evaluation of 3-year overall survival rates, 
3-year disease-free survival rates, and 3-year local recurrence rates. 
Secondary endpoints included 3-year distant recurrence rates, 3-year 
wound/port site recurrence rates, and quality of life. The 3-year overall 
survival rate was 67.8% for all patients. There was no difference in the 
3-year overall survival rates between the laparoscopic and open groups 
(68.4% Vs 6.7%, respectively, P=.55). This finding was also true within 
the rectal cancer cohort (P=.12). On subset analysis, there was no 
difference between the two modalities in 3-year overall survival rates 
among patients undergoing anterior resection (74.6% for the 
laparoscopic group Vs 66.7% for the open group, P=.17). This was also 
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true for patients undergoing APR (65.2% Vs 57.7%, respectively, 
P=.41). The 3-year disease-free survival rate for all patients within the 
study was 66.8%, with no difference observed between the two 
modalities (P=.70). This was again found to be true on separate analyses 
of patients with rectal cancer (P=.87). Three-year disease-free survival 
rates for patients undergoing anterior resection (70.9% for the 
laparoscopic group Vs 70.4% for the open group, P=.72) or APR (49.8% 
Vs 46.9%, respectively, P=.64) were not statistically different. The 3-
year local recurrence rate for all patients was 8.4%. Of particular note, 
among patients who underwent anterior resection, differences in CRM 
positivity did not translate into differences in 3-year local recurrence 
rates (7.8% for the laparoscopic group Vs 7.0% for the open group, 
P=.70). Additionally, the 3-year local recurrence rates for patients 
undergoing APR were not different between the treatment arms (15.1% 
Vs 21.1%, respectively, P=.47). However, the authors cautioned that 
further follow-up beyond the relatively short period of 3 years is required 
to ensure that a true difference does not become apparent in the long 
term. When looking at the secondary endpoints to the trial, the overall 3-
year distant recurrence rate was 14.9%. Once again, there was no 
statistical difference in distant recurrence rates for patients undergoing 
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anterior resection (13.3% for the laparoscopic group Vs 13.9% for the 
open group, P=.98) or APR (32.9% Vs 25.4%, respectively, P=.64). 
Within the trial, there were 10 wound/port site recurrences (2.5% Vs 
0.6%, respectively, P=.12). In the actual treatment group undergoing 
rectal resection (Vs the intention-to-treat population), the median 
hospital stay was 3 days shorter in the laparoscopic arm (10 days) 
compared with the open arm (13 days). However, this difference 
disappeared when comparing the open resection group with patients 
whose procedures were converted from laparoscopic to open. Of note, 
the overall (colon and rectal) conversion rate was 29%. However, this 
rate decreased with each year of the study (38% in year 1 to 16% in year 
6). Tumor fixation, uncertainty regarding tumor clearance, patient 
obesity, anatomic uncertainty, and technical inability to access some 
tumors laparoscopically contributed to the high conversion rate (34%) 
initially observed in rectal cancer patients undergoing laparoscopic 
surgery. Quality-of-life data involving 696 patients within the study 
showed no differences between the laparoscopic and open treatment 
arms in any of the function scales (body image, sexual function, sexual 
enjoyment, and future perspective) or symptom scales (micturition 
problems, adverse effects of chemotherapy, gastrointestinal symptoms, 
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male sexual problems, female sexual problems, defecation problems, 
stoma-related problems, and weight loss). These findings are similar to 
the short-term quality-of-life outcomes data reported by the COST trial, 
in which the only statistically significant difference observed between 
the laparoscopic-assisted colectomy and the open colectomy groups was 
the global rating score at 2 weeks following surgery.9 Mean global rating 
scale scores were 76.9 for the laparoscopic group vs 74.4 for the open 
colectomy group at 2 weeks (P=.009). The reasons for an apparent lack 
of significant difference in quality of life between the two groups have 
yet to be elucidated. The authors concluded that, in addition to adding to 
the growing body of evidence justifying the use of laparoscopic resection 
for colon cancer, the findings of their study (namely, that the higher 
CRM positivity seen after laparoscopic anterior resection has not 
translated into an increased incidence of local recurrence) extended to 
laparoscopic resection for rectal cancer. 
 Based on above trials, laparoscopic – assisted surgery is an 
acceptable alternative for resection of colon cancer with similar 
oncological outcomes & surgical morbidity while improving quality of 
life by reducing postoperative pain, hospital stay . Such evidence, 
however, are not yet available to support laparoscopic resection of rectal 
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cancer. Retrospective studies cautiously suggest the oncological 
adequacy of laparoscopic rectal resections.13,14 Although laparoscopic 
rectal resection appear safe, additional concerns regarding increased 
conversion rates and associated complications in laparoscopic rectal 
resection remain 2. 
 
 Several other aspects of laparoscopic rectal surgery are attractive 
for oncologic application. Total mesorectal resection is more commonly 
achieved in laparoscopic cohort, and appears to be technically easier, 
possible due to better visualization and magnification2. Additionaly, an 
interesting phenomenon of decreased tumor growth after laparoscopic 
surgery was observed in both animal studies15 and invitro studies 11 
 
 However, data regarding laparoscopic rectal cancer surgery is 
limited. The results of a prospective randomized trial of laparoscopic – 
assisted (n=51) versus open APR (n=48) for low rectal cancer reported 
by Ng et al 16 with the aim of comparing post-operative recovery course 
(primary endpoint) and survival data (secondary endpoint) between to 
groups. Postoperative recovery was found to be improved after 
laparoscopic – assisted APR with regard to earlier return of bowel 
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function (p=<.001), improved time to patient mobilization (p=0.05), and 
reduced analgesic requirement (p=.007), at the expense of prolonged 
operative time and higher direct cost. Survival probability at 5 years after 
curative resection was 75.2% for laparoscopic arm Vs 76.5% for open 
group (p=0.20). Disease free probabilities were not significantly 
different between two groups (p=.55). Findings of this study supported 
the view that there are clear short-term benefits to laparoscopic rectal 
resection with regard to functional recovery, as well as equivalent 
oncologic adequacy and survival.  
 
 Most recently, a large, single-institute retrospective review of 579 
patients who underwent laparoscopic resection for rectosigmoid and 
rectal cancer was reported by Ng et al,17 evaluating short-term outcomes 
and long-term survival. Over a period of 15 years, 316 patients 
underwent laparoscopic anterior resection, 152 patients had sphincter – 
preserving TME, and 92 patients underwent laparoscopic APR. After a 
median followup of 56 months, the study concluded that laparoscopic 
resection of rectal cancer is safe and offers long-term oncologic 
outcomes equivalent to those of open resections.  
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In a subsequent retrospective study of 421 patients (310 in the 
open group and 111 in the laparoscopic group) comparing outcome 
between open and laparoscopic resection for stage II and stage III rectal 
cancer, Law et al 18 reported 5-year actuarial survival rates of 71.1% Vs 
59.3% in the laparoscopic Vs open arms, respectively (P=.029). Median 
follow-up was 34 months, and there was no difference in local 
recurrence. In addition, laparoscopic resection was associated with 
decreased blood loss (200 mL Vs 350 mL, P< .001) and shorter hospital 
stay (7 Vs 9 days, P< .001). The conversion rate to open surgery was 
12.5%. On multivariate analysis, laparoscopic resection was an 
independent factor associated with improved survival (P=.03, hazards 
ratio 0.558 [95% confidence interval, 0.339–0.969]). It should be noted 
that there is no delineation of the number of stage II Vs stage III rectal 
cancer patients. In addition, of the 310 patients in the open group, 273 
(88.1%) underwent anterior resection, 31 (10%) APR, and 6 (1.9%) 
Hartmann's procedure. Within the laparoscopic group (n = 111), 102 
(91.9%) underwent anterior resection, 8 (7.2%) APR, and 1 (0.9%) 
Hartmann's procedure. The reason for the disproportionate number of 
anterior resections in both groups is unclear. Furthermore, although 
implied, it is not specifically stated that both mid and upper rectal 
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cancers were treated with anterior resection. Nonetheless, the study 
concluded that compared to open resection, laparoscopic resection for 
locally advanced rectal cancer is associated with more favorable overall 
survival. 
 
 Sufficient evidence now exists to support the implementation of 
laparoscopy as an acceptable modality in colectomy for cancer. Overall 
survival and recurrence data have proven that, from an oncologic 
standpoint, laparoscopic colectomy is equivalent to open colectomy. The 
data on laparoscopic resection for mid to low rectal cancer are limited to 
predominantly retrospective series and two prospective randomized 
trials. The initial nonsignificant but concerning finding of increased 
CRM positivity within the laparoscopic anterior resection cohort 
reported in the MRC CLASICC trial4 raised questions about oncologic 
adequacy. However, these concerns did not translate into a difference in 
local recurrence at 3 years between the laparoscopic and open 
approaches.19  
 
 Based on results of German rectal cancer study group 1 , 
preoperative chemoradiotherapy, as compared to postoperative 
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chemoradiotherapy was found to improve local control and was 
associated with reduced toxicity but there was no improvement in overall 
survival. However , there is limited data available on role of laparoscopic 
surgery for rectal cancer following neoadjuvant chemoradiation.  
 
 One of the largest study reported by Skrovina et al,20 compared 
laparoscopic rectal cancer surgery with or without neoadjuvant 
chemoradiation therapy. 81 patients received neoadjuvant treatment 
while 74 patients underwent primary laparoscopic surgery. Both groups 
were comparable in intraoperative (p=0.632) and postoperative surgical 
complications (p=0.179) and nonsurgical complications(p=0.654) too. 
Operative time and postoperative stay were similar in both groups. Yield 
of resected lymph node was significantly higher for primary surgery 
group (p<0.001). Overall short term results didn’t reveal worsening of 
perioperative period with neoadjuvant chemoradiotherapy. 
 
 Cheung Hy et al 21 evaluated perioperative short-term outcomes of 
laparoscopic rectal surgery after neoadjuvant chemoradiation therapy. 52 
patients in neoadjuvant group were compared with 138 patients in 
control group( primary surgery). Median operating time was 
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significantly higher in the neoadjuvant group as compared to control 
group (155 minutes versus 135 minutes respectively, p=0.09). There was 
no significant difference in terms of blood loss, conversion rates, 
postoperative morbidity, length of hospital stay or sphincter preservation 
rates. Overall five year survival rates in two group remained similar. 
Author concluded that patients after neoadjuvant chemoradiation for 
rectal cancer should not be deterred from minimally invasive approach 
as their data showed that, other than slightly longer operating time, 
laparoscopic rectal cancer surgery in patients with neoadjuvant 
chemoradiation is safe with no increased morbidity.  
 
 However another retrospective analysis by Rezvani et al 22 
revealed insignificantly higher conversion rate and significantly longer 
duration of surgery in laparoscopic rectal surgery following neoadjuvant 
chemoradiation. Although there was no difference in morbidity and 
mortality. Only 8 patients received neoadjuvant treatment while 52 
patients underwent primary surgery. Conversion rate was 37%( 3/8) in 
neoadjuvant group as compared to 13%(7/52) in primary surgical group. 
Operating time was longer in neoadjuvant group as compared to primary 
surgery (228 minutes versus 170 minutes respectively). Complication 
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rate and median number of harvested lymph nodes were similar in both 
groups.  
 
 Similary another retrospective study by R. Pugliese et al 23 showed 
that patients who underwent laparoscopic resection of rectal cancer after 
neoadjuvant chemoradiation had a significantly longer duration of 
surgery as compared to patients who didn’t receive neoadjuvant 
treatment (268 minutes versus 241 minutes respectively,p=0.004). 
conversion was needed in 9.5% (n=24) patients. However, none of the 
patient treated with neoadjuvant treatment required conversion. 
Morbidity and leak rates were not different significantly between two 
arms. 48 patients were treated with neoadjuvant chemoradiation. 38 
patients underwent laparoscopic low anterior resection(LAR) while 
laparoscopic abdomino-perineal resection was performed in 10 patients. 
Leak rate among laparoscopic LAR patients was not different between 
two groups. Average number of lymph nodes resected, were not 
significantly different between two groups. Distal resection margins 
were free in all patients in both groups. Author concluded that 
laparoscopic resection for rectal cancer is feasible and safe with 
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morbidity and long term results quite acceptable in patients receiving 
neoadjuvant chemoradiation. 
 
 Dan Geisler et al 24 did nonrandomized single arm study involving 
42 patients who received 5644 cGy of radiation therapy before 
laparoscopic surgery for rectal cancer and concluded that, with proper 
selection and laparoscopic experience, laparoscopic surgery can be 
performed in the irradiated pelvis without undue morbidity and 
mortality.  
 
 Ricardo Rosati et al25 reported no significant difference in 
operative time, in conversions to open surgery, in intra- and 
postoperative complications, and in anastomotic leakage rate between 
laparoscopic rectal surgery with or without neoadjuvant chemoradiation. 
In addition, they reported similar cumulative 3 and 5 year survival rates 
between two groups indicating oncological adequacy with laparoscopic 
surgery following neoadjuvant chemoradiation.  
 
 There are very few studies comparing laparoscopic surgery versus 
open surgery after neoadjuvant chemoradiation.  
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 Denoya P et 26 al performed retrospective analysis of all rectal 
cancer patients who received neoadjuvant chemoradiation. Between 
2002 to 2008, 64 patients were identified. 32 patients underwent 
laparoscopic surgery and 32 had laparotomy. Operative time was longer 
in the laparoscopic group (267+/- 76 versus 205+/- 49 minutes, p<0.001. 
Blood loss, complication rate, and mortality rate were all similar 
between two groups. However, the laparoscopic group benefited from 
shorter length of stay (6.1+/-2.4 versus 7.6+/-2.3 days, p=0.012), earlier 
first bowel movement (1.9+/-1 versus 3.3+/-2.4 days, p=0.006), and 
shorter time to regular diet(3.9+/-2.1 versus 5.8+/-2.5 days, p=0.003). 
There was no difference in lymph node harvest (both positive node 
harvest and total lymph node harvest), distal margin or radial margin. 
Overall it was found out that laparoscopic TME for rectal cancer was 
feasible and safe and patient benefitted from short-term advantages of 
laparoscopy.  
 
 The only prospective study to compare laparoscopic versus open 
abdomino-perineal resection following neoadjuvant chemoradiation was 
done by Araujo SE et al 27. 28 patients with distal rectal adenocarcinoma 
were randomized to undergo surgical treatment by laparoscopic APR 
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(n=13) or conventional open APR (n=15). There was no significant 
difference between two study groups regarding intra and post operative 
complications, need for blood transfusion, hospital stay after surgery, 
length of resected segment and pathological staging. Mean operation 
time was 228 minutes for laparoscopic APR versus 284 minutes for the 
conventional approach (p=0.04). Mean anaesthesia duration was shorter 
(p=0.03) for laparoscopic APR as compared to open APR. After a mean 
followup of 47 months and with exclusion of two patients in the open 
APR who presented with unsuspected synchronic metastasis during 
surgery, local recurrence was observed in two patients in the open APR 
and none in the laparoscopic group. However the sample size was very 
small to properly come for some recommendation.  
 
 Although laparoscopic rectal surgery following neoadjuvant 
chemoradiation has been found to be safe, with comparable oncological 
outcome with improvement in quality of life by reducing postoperative 
hospital stay, postoperative pain, less need for analgesics, reduced time 
to start diet , none of the studies have prospective with adequate sample 
size to come to any conclusion. Hence unless a properly randomized 
controlled trial is done, recommendation for superiority of laparoscopic 
or open surgery over one another can not be established. 
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MATERIAL AND METHODS 
 
 
 
 
 This study is a retrospective study, over a period of 6 years from 
January 2003 to april 2009 which included 251 patients. 192 patient 
underwent open surgery (Group I )as compared to 59 in laparoscopic 
surgery group( Group II). Neoadjuvant treatment was given to 131 
patients in group I Vs 52 in group II which represents the study 
population. Neoadjuvant concurrent treatment was given in the form of 2 
cycles of chemotherapy consisted of 5 Fu (325 mg/m2) & Mitomycin (6 
mg /m2) & 50 Gy of radiation therapy (1.8 to 2 Gy /day x 5 days). 
Surgery was performed about 6-8 weeks after neoadjuvant treatment. 
Preclinical staging was performed by a combination of history, physical 
examination, imaging by contrast enhanced CT scan of abdomen/pelvis. 
TNM classification (UICC) was used to classify tumors. Data were 
collected retrospectively for age, gender, pretreatment staging, duration 
of surgery, intraoperative blood loss, conversion to open surgery & 
postoperative data including morbidity, mortality & histopathology 
report. Exclusion criteria for laparoscopic surgery were significant 
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comorbid illnesses (i.e. diabetes, hypertension & ischemic heart disease), 
history of previous pelvic surgery, & adherence to other structures on 
imaging.  
 
Total case 
251
Open 192
NAT 
131  
None 
61
Lap 59
NAT 
52
None 
07
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SURGICAL PROCEDURE 
 
 
 
 
 Laparoscopy was performed using 4 port technique: 10 mm port 
infraumbilical and 5 mm ports in right and left lumber region and right 
iliac fossa region. Right lower port was positioned as low as possible, 
paying attention not to injure inferior epigastric vessels. In laparoscopic 
assisted low anterior resection, after laparoscopic mobilisation 
infraumbilical transverse laparotomy was done for retrieval of specimen 
& anastomosis. In laparoscopic abdominoperineal resection, specimen 
was removed through perineal wound. Laparoscopic harmonic scalpel 
was used to dissect & divide tissue. Inferior mesenteric vessels were 
dissected & ligated using ligaclips distal to origin of left colic vessels. 
Dorsal dissection was done in the avascular plane between parietal 
pelvic fascia and mesorectum , with preservation of the hypogastric 
nerve, sufficiently down to the floor of pelvis. Pelvic splanchnic nerves 
were preserved while doing lateral dissection. Thus, autonomic nerve 
preserving surgery were performed in principle except in those cases 
where extensive fibrosis subsequent to neoadjuvant chemoradiation 
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obscured tissue planes. Diversion transverse colostomy was done for all 
cases in low anterior resection. Postoperatively, APR patients and LAR 
patients with diversion colostomy were started liquids on 1st 
postoperative day which gradually increased to normal diet over a period 
of 3-4 days. Serial bladder catheter clamping usually started on 5th 
postoperative day to increase tonicity of bladder. Pelvic drains were 
removed at around 9th or 10th postoperative day. In all cases of APR and 
LAR in both groups, residual urine was checked with ultrasound of 
pelvis, after removal of bladder catheter and bladder was recatheterized 
if residual urine was reported to be more than 50 ml. These patients were 
then, discharged with catheter insitu and appropriate advice for 
maintenance of catheter and catheter clamping. Laparoscopic port site 
sutures removed on 9TH postoperative day. Perineal sutures were 
removed on 11th postoperative day in APR cases. Patients, who received 
neoadjuvant chemoradiation, were then referred for adjuvant 
chemotherapy.  
 
Statistical analysis:  
 
 Analysis was performed with SPSS software version 14 and p < 
0.05 was considered to be significant.  
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RESULTS 
 
 
 Gender ratio was equal in both groups (3:2). Mean age was more 
in group I (50.7 years Vs 48.6 years). Tumors in distal rectum (0-6cm) 
were more in group II (88.1% Vs 74.9 %) while middle rectal rectal 
tumors (6-12 cm) were more in group I (23.6% Vs 11.9%). There were 
no tumors in upper rectum in group II as compared to only 3 patients in 
group I (table 1). 
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Table 1. 
 
Patient characteristics 
Open
(n=192)
Lap 
(n=59)
M:F 3:2 3:2
Mean age 50.7 48.6
Distance from anal 
verge (cm)
0-6 74.9% (n=143) 88.1%(n=52)
6-12 23.6% (n=45) 11.9% (n=7)
>12 1.6% (n=3) nil
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Most of the patients in both groups were in stage IIa as shown in table 2. 
Table 2 
Stage distribution(n=207) 
APR+LAR+AR 
Stage NAT (n=160) % None(n=47) % 
 Open Lap Total Open Lap Total 
I a - -  - 14.2 2.1 
I b 10.9 18 13.1 25 28.5 25.5 
II a 70 68 69.3 55 57.1 55.3 
II b 8.2 8 8.1 5 - 4.2 
III a 2.7 6 3.7 - - - 
III b 6.3 - 4.3 2 - 2.1 
IV 1.8 - 1.2    
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 Most of the surgeries were APR, LAR or AR in both groups [table 
3]. There was no significant difference in median duration of surgery in 
two arms (265 minutes for open surgery Vs 270 minutes for laparoscopic 
group). Similarly median hospital stay was same in both groups (15 
days). However, mean blood loss was significantly less in group II (585 
ml Vs 300 ml) [table 4]. Conversion rate to laparotomy was 3.8% (2/52) 
in laparoscopic rectal surgery following chemoradiation as 
intraoperatively lesion was found to be adherent posteriorly. 
Circumferrential resection margin was not significantly different in two 
groups with or without neoadjuvant chemoradiation [table 5,6,7]. There 
was no significant difference in mean nodal yield between two arms as 
shown in [table 8]. Although mean nodal yield appeared to be less in 
both arms (post neoadjuvant chemoradiation) but on a subset analysis 
mean nodal yield was found to be significantly less in open APR after 
neoadjuvant chemoradiation as compared to upfront open APR ( 8.51 
versus 19) [table 9] . There was no significant difference in overall 
morbidity as well as minor (<30 days hospital stay) and major morbidity 
(>30 days hospital stay) when comparing major surgical procedures 
performed in both arms [table 10a]. Similarly there were no significant 
differences in perineal morbidity after APR in both arms [table 11]. 
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Urinary morbidity in the form of urinary tract infection and prolonged 
catheterization was almost same following APR & LAR irrespective of 
neoadjuvant chemoradiation as shown in [table 12]. There was no 
significant difference between patients undergoing open or laparoscopic 
LAR [table 13]. 
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Table 3 
Surgery Open Laparoscopic Total
APR 82 45 127 
LAR 57 09 66 
AR 11 03 14 
Exenteration procedures 15 01 16 
Hartmann’s procedure 07 00 07 
Total colectomy, ileorectal anastomosis 04 00 04 
Total proctocolectomy 06 01 06 
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Table 4 
 
 Open Lap p value 
Median duration of sx 265 minutes 270 minutes Ns 
Mean blood loss 585 ml 300 ml <0.001 
Median hospital stay 15 days 15 days Ns 
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Table 5 
CRM ( APR+LAR: n=193) 
 
CRM distance 
Open 
(n=97) 
Lap 
(n=45) 
p value 
>2 mm 
83.5% 
(n=81) 
80% 
(n=36) 
Ns 
<2 mm 
16.4% 
(n=16) 
20% 
(n=09) 
Ns 
Total 97 45 142 
 
          Note: CRM distance not available in 51 cases.  
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Table:6   CRM (Post NAT: n=113) 
 
CRM distance Open Lap p value 
>2mm 84.7%(n=61) 80.4%(n=33) Ns 
<2mm 15.2%(n=11) 19.5%(n=08) Ns 
Total 63.7%(n=72) 36.2%(n=41) 113 
 
 
Table:7   Positive CRM 
 
 Open Lap p value 
PostNAT(n=160) 4.5%( 5/110) 4%(2/50) Ns 
None (n=193) 5%(7/139) 3.7%(2/54) Ns 
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Table 8: Mean nodal yield 
 
 Year Open Lap p value 
APR+LAR 
Post NAT 
(n=161) 
2003-2009 
8.32 
(n=110) 
6.96 
(n=51) 
Ns 
2003-2005 
7.32 
(n=37) 
6.88 
(n=26) 
Ns 
2006-2009 
8.82 
(n=74) 
7.04 
(n=24) 
Ns 
 
 
Table 9: Nodal yield after APR 
 
 NAT None p value 
Open APR 8.51 19 0.005 
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Table 10:  Morbidity 
  
Open 
(n=150) 
Lap 
(n=57) 
p 
value 
Overall morbidity 
APR+LAR+AR 
(n=207) 
Minor 
39.3%   
(n=59) 
36.8%  
(n=21) 
Ns Major 
10.6%  
(n=16) 
21%  
(n=12) 
Total 
50%  
(n=75) 
57.8%  
(n=33) 
Mortality 
  Nil Nil  
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Table 10 b  Breakup of overall morbidity 
 
Morbidity APR LAR AR Total 
Nil 58 34 9 101 
Perineal wound 42 NA NA 42 
Abdominal wound 4 14 3 21 
Urinary 19 13 O 32 
Others 4 5 1 10 
Anastomotic leak NA 0 1 01 
 127 66 14 207 
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Table 11: 
 
Perineal morbidity  Open Lap p value 
APR 
(n=127) 
Minor 
14.6% 
(n=12) 
15.5% 
(n=07) 
Ns Major 
13.4% 
(n=11) 
26.6% 
(n=12) 
Total 
28% 
(n=23/82) 
42.2% 
(n=19/45) 
Post NAT APR 
(n=113) 
Minor 
16% 
(n=11) 
16% 
(n=07) 
Ns Major 
16% 
(n=11) 
27.2% 
(n=12) 
Total 
31.8% 
(n=22/69) 
43% 
(n=19/44) 
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Table 12: 
  Open Lap p value 
Urinary 
morbidity 
(n=193) 
APR+LAR) 
With NAT 
14.54% 
(n=16/110) 
14% 
(n=07/50) 
Ns 
Without 
NAT 
24.13% 
(n=07/29) 
25% 
(n=01/04) 
Total 23 08 
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Table 13: Morbidity after Low anterior resection 
 
Morbidity 
Open 
(n=57) 
Lap 
(n=9) 
p value 
Nil 
50.8% 
(n=29) 
55.5% 
(n=5) 
Ns 
Abdominal 
wound 
22.8% 
(n=13) 
11.1% 
(n=1) 
Urinary 
19.2% 
(n=11) 
22.2% 
(n=2) 
Others 
7% 
(n=4) 
11.1% 
(n=1) 
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DISCUSSION 
 
 
 
 Laparoscopic assisted surgery for colon cancer is an accepted 
alternative as it has shown comparable results in terms of morbidity, 
intraoperative complications, postoperative complications and equal 
oncological outcomes. But similar data is not available for laparocopic 
rectal cancer surgery. Further more there is paucity of data for doing 
laparoscopic surgery for rectal cancer following neoadjuvant 
chemoradiation.  
 
 This study was done to compare short-term outcomes between 
laparoscopic and open surgery for rectal cancer following neoadjuvant 
chemoradiation . Laparosopic surgery for rectal cancer was started in 
cancer institute in mid 2003. Locally advanced rectal cancer form almost 
2/3rd of all cases. Neoadjuvant chemoradiation is practiced in our 
institute for locally advanced rectal cancer. Hence most of the patients 
usually undergo surgery after chemoradiation. 
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 Operative time was longer in most of the series, 21,22,23 similar to 
our series which may be due to post chemoradiation fibrosis & difficulty 
in dissecting tissue planes . Most of the series didn’t show any difference 
in intraoperative blood loss. However, in our series, mean blood loss was 
significantly less in laparoscopic arm as compared to open surgery. 
Nodal yield was significantly less in chemoradiation arm in series by 
skrovina et al 20 but this was a comparison between laparoscopic rectal 
surgery with or without chemoradiation. Although other series 
comparing laparoscopic surgery with or without chemoradiation21,22,23 
reported similar nodal yield between both groups. In open rectal surgery, 
different series 28,29,30 have reported significantly higher nodal yield with 
upfront surgery as compared to surgery after neoadjuvant 
chemoradiation. There was no significant difference in nodal yield in our 
series. Infact when entire study period was divided in two equal halves, 
there was a trend towards better nodal yield in later half of study period 
in laparoscopic group. Overall nodal yield is relatively less in our series( 
mean 6.96 ) as compared to other series with laparoscopic surgery after 
neoadjuvant chemoradiation 23,25 ( mean 12-13 nodes). But as already 
shown in [table 7] that even in open APR, nodal yield was significantly 
less after chemoradiation as compared to upfront APR. Reason for less 
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nodal yield could be higher dose of radiation in our study (50 Gy in our 
study as compared to 45 Gy in other series 23,25). Other factor could be 
use of two drugs (5 Fu and Mitomycin ) in our study as compared to 5-
Fu alone in other series 23,25. Series which compared laparoscopic rectal 
surgery with or without neoadjuvant chemoradiation did not show any 
significant difference in intraoperative, postoperative complications, 
postoperative hospital stay. Oncological safety in terms of 
circumferential resection margin and distal margin status was not 
significantly different in our study. Postoperative morbidity and 
mortality were similar in both arms. Studies comparing laparoscopic 
rectal surgery with open rectal surgery following neoadjuvant 
chemoradiation are very few. Operative time was longer in one 
retrospective series 26 like our series but other prospective series 27 
reported decresed operative time .Hospital stay was shorter in 
laparoscopic arm in Denoya P et al 26series but in our series length of 
postoperative hospital stay is same for both arms (median hospital stay- 
15 days) as most of the patients are from rural areas & they wanted to 
have sutures removed before getting discharge. Other factor may be 
removal of bladder catheter which usually taken out at around 10 days 
after surgery (for APR or LAR). Perineal morbidity per se has not been 
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addressed separately in any of the series. In our study, major perineal 
wound morbidity (more than 30 days postoperative hospital stay) was 
high in laparoscopic rectal surgery group as compared to open surgery 
group, although it was not significant. Reason for this may be that after 
removal of specimen we routinely fill pelvic cavity with omentum in 
open surgery while it was not done in laparoscopic surgery. So once 
there was perineal wound breakdown, it took longer time to heal in 
laparoscopic rectal surgery due to large pelvic cavity. While in open 
surgery perineal wound healed faster because of small pelvic cavity due 
to presence of omentum. Major perineal morbidity was higher even in 
patients who underwent laparoscopic APR without neoadjuvant 
chemoradiation suggesting that a higher rate of perineal wound 
morbidity may not be due to chemoradiation alone but also due to 
differencs in operative procedures in the present study. The omentum 
possesses many physiologic properties that make it favourable for use as 
a flap in the pelvis after APR. It plays a major role in local immune 
response. Angiogenic properties of the omentum create vascular 
adhesions that may provide an alternate blood supply to surrounding 
ischemic tissues 31,32. Furthermore, the omentum contains high 
concentration of tissue factor giving it significant hemostatic 
  47
properties33. These physiologic properties and its capacity to fill the 
pelvic dead space make the omentum an excellent candidate for tissue 
transfer to the pelvis. Several studies have reported good results with the 
use of omental pedicle flaps in the pelvis and perineum, with a 50 to 
100% primary perineal wound healing rate 34,35,36. However, a 
prospective non-randomized multicenter trial reported that omentoplasty 
after APR for cancer conferred no significant advantage in perineal 
wound healing compared with patients without omentoplasty 37. A recent 
modification of the omentoplasty to include suturing of the omentum to 
the perineal subcutaneous tissue before perineal skin closure has resulted 
in an 80% primary perineal wound healing rate 36. Collectively, these 
studies suggest that the omental pedicle flap is effective when sufficient 
in size to reach the pelvis and perineum. Distal margin was negative in 
all cases of low anterior resection and anterior resection in both groups. 
Conversion rate was 3.8% ( 2/52) in our series as compared to 5% in 
other series 25 . There were no conversions in neoadjuvant 
chemoradiation group in series by Pugliese et al 23. Absence of 
anastomotic leak in our series may be explained by construction of 
covering stoma in all cases. 
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Duration 
of surgery
Overall 
morbidity Leaks
Conversion 
rate 
Mean 
blood loss 
Nodal 
yield 
R.Pugliese et al 
(lap=48) 
EJSO,35;2009:497-
503 
 
More in 
NAT 
 
No 
difference
 
7.9%
 
Nil 
 
No 
difference 
 
Equal 
Rezvani et al  
(lap =8) 
JSLS 
2007(11):204-207 
 
More in 
NAT 
 
No 
difference
 
Nil 
 
37% 
 
No 
difference 
 
Equal 
Cheung et al  
(lap = 52) 
Surgical endoscopy 
2008 sep 19 
 
More in 
NAT 
 
No 
difference
 
Nil 
 
Nil 
 
No 
difference 
 
Equal 
Araujo et al  
(lap=13) 
Rev hosp med clin 
fac med sao paulo 
2003 may-
june;58(3):133-40 
 
Less in lap
 
No 
difference
 
Nil 
 
Nil 
 
No 
difference 
 
Equal 
Skrovina et al  
(lap =81) 
Rozhl chir2008 
aug;87(8):417-25 
 
No 
difference
 
No 
difference
 
Nil 
 
Nil 
 
No 
difference 
 
Less in lap
 
Cancer institute  
( WIA ) 
(Lap=52)   
No 
difference
No 
difference Nil 3.3% 
Less in 
lap 
No 
difference
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LIMITATIONS 
 
 
 
 
 Our study is one of the largest reported study to date regarding 
number of patients with laparoscopic rectal surgery following 
neoadjuvant chemoradiation (n=52). However, there are several 
important limitations of this study. First, this was a retrospective study 
hence assessment of need for postoperative analgesia, in terms of days 
and doses could not be assessed. Second, this was not a randomized 
study. Third, long term follow-up was lacking as cases were considered 
for inclusion in study till mid 2009. Hence long term oncological data in 
terms of local recurrence, disease free survival and overall survival are 
lacking.  
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CONCLUSION 
 
 
 
 Present study suggests that laparoscopic surgery for rectal cancer 
can be performed after neoadjuvant chemoradiation with equal morbidity 
and oncological safety with significantly less blood loss. This needs 
confirmation by prospective randomized trials.  
  51
 
 
 
REFERENCES 
 
 
 
 
1. Rolf Sauer, M.D., Heinz Becker, M.D.,Werner Hohenberger, 
M.D., Claus Rodel , M.D., Christian Wittekind , M.D., Rainer 
Fietkau, M.D., Peter Martus, Ph.D., Jorg Tschmelitsch,M.D., Eva 
Hager, M.D., Clemens F. Hess, M.D., Johann- H. Karstens, M.D., 
Torsten Liersch, M.D., Heinz Schmidberger , M.D., and Rudolf 
Raab, M.D., for the German Rectal Cancer Study Group. N Engl J 
Med 2004;351:1731-40. 
2. Pierre J Guillou, Philip Quirke, Helen Thorpe, Joanne Walker, 
David G Gayne, Adrian M H Smith, Richard M Heath, Julia M 
Brown, for the MRC CLASSIC trial group. Lancet 
2005;365:1718-26. 
3. Parkin KM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer 
J Clin 1999;49(1):33 
4. Heald R J, Moran B J,Ryall R D, Sexton R, MacFarlane J K. The 
Basingstoke experience of total mesorectal excision 1978-1997. 
Arch Surg 1998;133:894-899. 
  52
5. Enker W E, Thaler H T, Cranor M L, Polyak T. Total mesorectal 
excision in the operative treatment of carcinoma of the rectum. J 
Am Coll Surg 1995;181:335-346. 
6. Cicil D T, Sexton r, Moran B J, Heald R J. Total mesorectal 
excision results in low local recurrence rates in lymph node- 
positive rectal cancer. Dis Colon Recum 2004;47:1145-1150. 
7. Nezhat F, Nezhat C, Pennington E. Laparoscopic proctectomy for 
infiltrating endometriosis of the rectum. Fertil Steril. 
1992;57:1129-1132. 
8. Philips EH, Franklin M, Carroll BJ, Fallas MJ, Ramos R, 
Rosenthal D. Laparoscopic colectomy. Ann Surg 1992;216:703-7. 
9. Heidi Nelson, Danile J. Sargent, H.Sam Wieand, James Fleshman, 
Mehran Anvari, Steven J.Stryker, Robert W.Beart, Michael 
Hellinger, Richard Flanagan, Walter Peters, David Ota. A 
comparison of Laparoscopically assisted and open colectomy for 
colon cancer. The clinical outcomes or surgical therapy study 
group. N Engl J Med 2004;350:2050-9. 
10. Antonio M Lacy, Juan C Garcia-Valdecasas, Salvadora Delgado, 
Antoni Castells, PilarTaura, Josep M Pique, Josep Visa. 
Laparoscopic-assisted colectomy versus open colectomy for 
  53
treatment of non-metastatic colon cancer: a randomised trial. 
Lancet 2002;359:2224-29. 
11. Leng J, Lang J, Jiang Y, Liu D, Li H. Impact of different 
pressures and exposures times of a simulated carbon dioxide 
pneumoperitoneum environment on proliferation and apoptosis of 
human ovarian ovarian cancer cell lines. Surg Endosc. 
2006;20:1556-59. 
12. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery 
versus open surgery for colon cancer: short-term outcomes of a 
randomised trial. Lancet Oncol. 2005;6:477-484. 
13. Scheidbach H, Schneider C, Konradt J, et al. Laparoscopic 
abdominoperineal resection and anterior resection with curative 
intent for carcinoma of the rectum. Surg Endos. 2002;16:7-13. 
14. Baker RP, White EE, Titu L, Duthie GS, Lee PW, Monson JR. 
Does laparoscopic abdominoperineal resection of the rectum 
compromise long-term survival? Dis Colon Rectum. 
2002;45:1481-1485. 
15. Bouvy ND, Marquet RL, Jeelel J, Bonjer HJ. Laparoscopic 
surgery is associated with less tumor growth stimulation than 
  54
conventional surgery: an experimental study. Br J Surg . 
1997;84:358-361. 
16. Ng SS, Leung KL, Lee JF, et al. Laparoscopic-assisted versus 
open abdominoperineal resection for low rectal cancer: a 
prospective randomized trial. Ann Surg Oncol. 2008;15(9):2418–2 
425. 
17. Ng KH, Ng DC, Cheung HY, et al. Laparoscopic resection for 
rectal cancers: lessons learned from 579 cases. Ann Surg. 
2009;249(1):82–86. 
18. Law WL, Poon JT, Fan JK, et al. Comparison of outcome of open 
and laparoscopic resection for stage II and stage III rectal cancer. 
Ann Surg Oncol. 2009;16(6):1488–1 493. 
19. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of 
laparoscopic-assisted resection of colorectal carcinoma: 3-year 
results of the UK MRC CLASICC Trial Group. J Clin Oncol. 
2007;25(21):3061–3 068. 
20. Skrovina M, Bartos J, Soumarova R, Czudek S, Parvez J, Bartos 
P, Adamcik L, Kokavec V. Laparoscopic resection of rectal 
cancer: evaluation of perioperative results of the primary resection 
  55
and resection after preoperative chemoradiotherapy. Rozhl Chir 
2008 Aug;87(8):417-25. 
21. Cheung HY, Chung CC, Wong JC, Yau KK, Li MK. 
Laparoscopic rectal cancer surgery with and without neoadjuvant 
chemo-irradiation: a comparative study. Surg Endosc 2008 sep 19. 
22. Masoud Rezvani, Jan Franko, Steven A. Fassler, Steven G.Harper, 
Joseph H.Nejman, D.Mark Zebley. Outcomes in patients treated 
by laparoscopic resection of rectal carcinoma after neoadjuvant 
therapy for rectal cancer. JSLS(2007)11:204-207. 
23. R.Pugliese, S.Di Lernia, F. Sansonna, D.Maggioni, G.C. Ferrari, 
C.Magistro, A.Costanzi, S.De Carli, S.Artale, F.Pugliese. 
Laparoscopic resection for rectal adenocarcinoma. EJSO 35 
(2009)497-503. 
24. Dan Geisler, John Marks, Gerald Marks. Laparoscopic colorectal 
surgery in the irradiated pelvis. Am J of Surg vol 2004 sep;188(3): 
267-270. 
25. Ricardo Rosati, Stefano Bona, Uberto Fumagalli Romario, Ugo 
Elmore, Niccolo Furlan. Laparoscopic total mesorectal excision 
after neoadjuvant chemoradiotherapy. Surgical Oncology (2007) 
16, S83-S89 
  56
26. Denoya P, Wang H, Sands D, Nogueras J, Weiss E, Wexner SD. 
Short term outcomes of laparoscopic total mesorectal excision 
following neoadjuvant chemoradiotherapy. Surg Endosc, 2009 oct 
23. 
27. Araujo SE, da Silva eSousa AH Jr, de Campos FG, Habr-Gama 
A,Dumarco RB, Caravatto PP, Nahas SC, da Silva J, Kiss 
DR,Gama-Rodrigues JJ. Conventional approach x laparoscopic 
abdominoperineal resection for rectal cancer treatment after 
neoadjuvant chemoradiation:results of a prospective randomized 
trial. Rev Hosp Clin Fac Med Sau Paulo.2003 May-
Jun;58(3):133-40. 
28. B.Morcos, B.Baker, M. Al Masri, H.Haddad, S.Hashem. Lymph 
node yield in rectal cancer surgery : Effect of preoperative 
chemoradiotherapy. EJSO 36(2010) 345-349. 
29. Rullier A, Laurent C, Capdepont M, et al. Lymph nodes after 
preoperative chemoradiotherapy for rectal carcinoma: number, 
status , and impact on survival. Am J Surg Pathol 2008;32:45-50. 
30. Wichmann MW, Muller C, Meyer G, et al. Effect of preoperative 
radiotherapy on lymph node retrieval after resection of rectal 
cancer. Arch Surg 2002;137:206-10. 
  57
31. Doherty NS, Griffiths RJ, Hakkinen JP, Scampoli DN, Milici AJ. 
Post capillary venules in the “milky spots” of the greater omentum 
are the major site of plasma protein and leukocyte extravasation in 
rodent models of peritonitis. Inflamm Res 1995;44:169-177 
32. Goldsmith HS, Griffith AL, Kupferman A, Catsimpoolas N. Lipid 
angiogenic factor from omentum. JAMA 1984;252:2034-2036 
33. Logmans A, Schoenmakers CH, Haensel SM, et al. High tissue 
factor concentration in the omentum, a possible cause of its 
hemostatic properties. Eur J Clin Invest 1996;26:82-83 
34. Moreaux J, Horiot A, Barrat F, Mabille J. Obliteration of the 
pelvic space with pedicled omentum after excision of the rectum 
for cancer. Am J Surg 1984;148:640-644 
35. John H, Buchmann P. Improved perineal wound healing with the 
omental pedicle graft after rectal excision. Int J Colorectal Dis 
1991;6:193-196 
36. De Broux E, Parc Y, Rondelli F, Dehni N, Tiret E, Parc R. 
Sutured perineal omentoplasty after abdominoperineal resection 
for adenocarcinoma of lower rectum. Dis Colon Rectum 
2005;48:476-482 
  58
37. Hay JM, Fingerhut A, Paquet JC, Flamant Y. Management of the 
pelvic space with or without omentoplasty after abdominoperineal 
resection for carcinoma of rectum: a prospective multicentre study 
. The French association for Surgical Research. Eur J Surg 
1997;163:199-206. 
